Rumi, Elisa <br/><br/>
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.  [electronic resource] 

 -  Blood  Mar 2014 
 - 1544-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2013-11-539098  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alleles<br/>Calreticulin--genetics<br/>Cell Transformation, Neoplastic--genetics<br/>Codon<br/>Exons<br/>Female<br/>Granulocytes<br/>Humans<br/>Janus Kinase 2--genetics<br/>Male<br/>Middle Aged<br/>Mutation<br/>Myeloproliferative Disorders--genetics<br/>Polycythemia Vera--genetics<br/>Primary Myelofibrosis--genetics<br/>Prognosis<br/>Receptors, Thrombopoietin--genetics<br/>Thrombocythemia, Essential--diagnosis<br/>Thrombosis--genetics<br/>Young Adult